About us

Founded in 2014, Saphetor (which means “interpreter” in ancient greek) is a precision medicine company at the cutting edge of genome-scale analysis based on Next Generation Sequencing (NGS). Capitalizing on the emerging trend in NGS to use large “panels” of genes, exomes, or whole genomes, Saphetor’s suite of services offers clinicians intuitive, data-driven solutions to make faster, more accurate diagnoses, and informed decisions for the selection of the best therapies, especially for cancer and difficult to diagnose conditions, such as rare diseases or cognitive impairment.

  • End "diagnostic odyssey"

    by facilitating accurate diagnoses of diseases that had previously been difficult to identify

  • Allow selection of optimal/targeted therapies

    by identifying genetic pathways causing disease

  • Stratify patients for clinical trials

    by confirming genetic variation(s) being targeted

  • Perform sub-population analysis to improve drug development

    by identifying variations that correlate with differences in efficacy/tolerability

  • Discover/validate new drug targets and/or biomarkers for diagnostics

    by identifying variants that correlate with phenotype(s) of disease

Management Team

We are a highly complementary team bringing together strong competencies in Genetics, Informatics and Business Development
Andreas Massouras, PhD

Andreas Massouras, PhD

Founder - CEO

Prior to founding Saphetor in 2014, Andreas had a proven track record in creating value from big data analysis. During his first career in the financial industry, working for leading investment banks Salomon Brothers, Credit Suisse, and Citigroup (where he was Managing Director), he developed advanced data analysis tools that were used in financial products for clients as well as in proprietary trading. After 16 years in finance, Andreas began a second career by becoming one of the pioneers in applying big data and computer science know-how to genetics. He received a PhD in Computational Genetics from the Swiss Federal Institute of Technology, Lausanne (EPFL) in 2013 and a MEng in Software Engineering from Imperial College London in 1992.

Yannick Romero, PhD

Yannick Romero, PhD

Head Business Development

Yannick has a PhD in Biology from the University of Geneva in 2011. He then successfully contributed to the set-up and growth of a start-up in the preclinical in vivo pharmacology field as principal investigator and was promoted to business development director. He was accountable for all aspects of Business Development related to preclinical services, including building and maintaining the customer base, building the company’s visibility and brand name, and developing partnerships and collaborations with the Pharma/Biotech industry. He contributed to scientific decisions regarding innovative science, participated actively to fundraising and defined overall business strategy. Yannick is a certified Project Manager who contributes a rare combination of sound scientific knowledge with strong business acumen and vision. Since January 2016, he serves as Head of Business Development at Saphetor.

Scientific Advisors

Nazneen Rahman, M.D, PhD.

Professor Nazneen Rahman is Head of the Division of Genetics and Epidemiology at The Institute of Cancer Research and Head of the Cancer Genetics Clinical Unit at The Royal Marsden NHS Foundation Trust, United Kingdom. She is also Director of an NGS clinical diagnostics laboratory, TGLclinical. She qualified in medicine from Oxford University, United Kingdom, in 1991 and completed a PhD in Molecular Genetics in 1999. Professor Rahman has extensive experience and knowledge in the identification, translation and clinical utilisation of disease genes, particularly in cancer genomics.

Vladimir Katanaev, PhD.

Vladimir Katanaev received his PhD in 2000 from the Institute of Biochemistry, Univ. of Fribourg. From 2000 to 2005 he worked as post-doc and as associate research scientist at the Dpt. of Genetics and Development of Columbia Univ., NY, where he started his research on the Wnt/Frizzled signaling. He continued to study this signaling cascade as a group leader at the Univ. of Konstanz. He joined the Dpt. of Pharmacology and Toxicology in April 2011 as associate professor, relocating his laboratory from Konstanz to Lausanne.

Zoltán Kutalik, PhD.

Zoltán is trained as mathematician. MPhil degree in 2003 at the Univ. of Manchester IST and PhD in 2006 at the School of Computing Sciences, Univ. of East Anglia, Norwich, UK & the Computational Microbiology Lab, IFR. 2006-2010 Zoltán was a post-doc in the Computational Biology Group (UNIL) and affiliated with the Swiss Institute of Bioinformatics.
In 2011 Zoltán became junior lecturer at the Dpt of Medical Genetics and in 2013 was nominated as assistant professor at the Institute of Social and Preventive Medicine (IUMSP) at the Lausanne Hospital (CHUV). He holds an honorary senior lecturer position at the Univ. of Exeter.

Alexandre Reymond, PhD.

Professor Alexandre Reymond received his Ph.D. at the Swiss Institute of Experimental Cancer Research in 1993. After completion of his postdoctoral training with Dr Roger Brent in the Department of Molecular Biology, Massachusetts General Hospital and in the Department of Genetics, Harvard Medical School in Boston, he moved to the Telethon Institute of Genetics and Medicine (TIGEM) in Milan in 1998 to lead a research group. He joined in 2000 the Department of Genetic Medicine and Development, University of Geneva Medical School. He moved to the Center for Integrative Genomics (Lausanne) in October 2004 and became its Director in 2015.

Saphetor is a member of the Global Alliance for Genomics & Health